BR112015002295A2 - métodos e composições para indução in vivo de formação de célula beta pancreática - Google Patents

métodos e composições para indução in vivo de formação de célula beta pancreática

Info

Publication number
BR112015002295A2
BR112015002295A2 BR112015002295A BR112015002295A BR112015002295A2 BR 112015002295 A2 BR112015002295 A2 BR 112015002295A2 BR 112015002295 A BR112015002295 A BR 112015002295A BR 112015002295 A BR112015002295 A BR 112015002295A BR 112015002295 A2 BR112015002295 A2 BR 112015002295A2
Authority
BR
Brazil
Prior art keywords
beta cell
compositions
methods
pancreatic beta
cell formation
Prior art date
Application number
BR112015002295A
Other languages
English (en)
Other versions
BR112015002295B1 (pt
Inventor
Doiron Bruno
A Defronzo Ralph
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112015002295A2 publication Critical patent/BR112015002295A2/pt
Publication of BR112015002295B1 publication Critical patent/BR112015002295B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01002—Glucokinase (2.7.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

resumo “métodos e composições para indução in vivo de formação de célula beta pancreática” as modalidades da invenção estimulam três níveis de fisiologia de célula beta: (i) metabolismo de glicose, (ii) função de receptor de membrana e (iii) fatores transcricionais que resultam na formação in vivo de células beta no pâncreas para a finalidade de tratamento de diabetes. 1/1
BR112015002295-2A 2012-07-31 2013-07-31 Método para induzir a formação de célula beta in vitro BR112015002295B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261678077P 2012-07-31 2012-07-31
US61/678,077 2012-07-31
PCT/US2013/052820 WO2014022455A1 (en) 2012-07-31 2013-07-31 Methods and compositions for in vivo induction of pancreatic beta cell formation

Publications (2)

Publication Number Publication Date
BR112015002295A2 true BR112015002295A2 (pt) 2018-05-08
BR112015002295B1 BR112015002295B1 (pt) 2022-02-01

Family

ID=50028488

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015002295-2A BR112015002295B1 (pt) 2012-07-31 2013-07-31 Método para induzir a formação de célula beta in vitro

Country Status (18)

Country Link
US (3) US9649344B2 (pt)
EP (1) EP2880167B1 (pt)
JP (2) JP6371765B2 (pt)
KR (1) KR102100093B1 (pt)
CN (1) CN104736711B (pt)
BR (1) BR112015002295B1 (pt)
CA (2) CA2880691C (pt)
CY (1) CY1120800T1 (pt)
DK (1) DK2880167T3 (pt)
ES (1) ES2679394T3 (pt)
HR (1) HRP20181124T1 (pt)
HU (1) HUE039520T2 (pt)
LT (1) LT2880167T (pt)
MX (1) MX360824B (pt)
PL (1) PL2880167T3 (pt)
PT (1) PT2880167T (pt)
SI (1) SI2880167T1 (pt)
WO (1) WO2014022455A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CN105412094A (zh) 2009-07-06 2016-03-23 爱尔皮奥治疗有限公司 用于防止癌细胞转移的化合物、组合物和方法
JP2014530244A (ja) 2011-10-13 2014-11-17 エアピオ セラピューティックス， インコーポレイテッド 血管漏出症候群および癌を治療する方法
EP2880167B1 (en) * 2012-07-31 2018-04-18 The Board of Regents of The University of Texas System Methods and compositions for in vivo induction of pancreatic beta cell formation
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
KR20180054677A (ko) 2015-09-23 2018-05-24 에르피오 세러퓨틱스 인코포레이티드 Tie-2의 활성화제로 안내압을 치료하는 방법
EP4399276A2 (en) * 2021-09-09 2024-07-17 Flagship Pioneering Innovations VI, LLC Methods and compositions for modulating goblet cells and for muco-obstructive diseases
WO2023225603A2 (en) * 2022-05-20 2023-11-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Insulin promoter for gene therapy for type 2 diabetes mellitus

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5383848A (en) * 1990-04-12 1995-01-24 Gensia, Inc. Iontophoretic administration of drugs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
JP2003189875A (ja) * 2001-12-28 2003-07-08 Japan Science & Technology Corp 膵β細胞関連転写因子の遺伝子導入によるインスリン産生細胞の形成誘導
AU2003221140B9 (en) 2002-03-26 2009-07-30 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
JP4136434B2 (ja) 2002-04-17 2008-08-20 進 清野 インスリン産生細胞の誘導
GB0227813D0 (en) 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
JP2009502078A (ja) 2005-07-20 2009-01-22 エヌエックスピー ビー ヴィ 精密ｏｆｄｍシンボル同期化のための方法及び同期装置並びにｏｆｄｍシンボルの受信のための方法／受信器
CA2557635C (en) 2005-08-31 2014-10-28 Lifescan, Inc. Methods to promote cell differentiation
EP1966152A2 (en) 2005-12-20 2008-09-10 Takeda Pharmaceutical Company Limited Glucokinase activators
PL2463283T3 (pl) 2006-04-20 2014-10-31 Pfizer Prod Inc Skondensowane fenyloamidowe związki heterocykliczne do zapobiegania i leczenia chorób pośredniczonych przez glukokinazę
CN101808995A (zh) * 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
WO2010022395A2 (en) * 2008-08-22 2010-02-25 President And Fellows Of Harvard College Methods of reprogramming cells
EP2393926A1 (en) * 2009-02-03 2011-12-14 F. Hoffmann-La Roche AG Compositions and methods for inhibiting expression of ptp1b genes
JP5681955B2 (ja) 2010-10-08 2015-03-11 ミナ セラピューティクス リミテッド 短いｒｎａ分子
EP2880167B1 (en) * 2012-07-31 2018-04-18 The Board of Regents of The University of Texas System Methods and compositions for in vivo induction of pancreatic beta cell formation

Also Published As

Publication number Publication date
JP6371765B2 (ja) 2018-08-08
US20150190432A1 (en) 2015-07-09
MX360824B (es) 2018-11-15
JP2018172430A (ja) 2018-11-08
CA3012929A1 (en) 2014-02-06
CA2880691A1 (en) 2014-02-06
EP2880167B1 (en) 2018-04-18
BR112015002295B1 (pt) 2022-02-01
MX2015001448A (es) 2015-07-14
SI2880167T1 (sl) 2018-12-31
US10980841B2 (en) 2021-04-20
CA3012929C (en) 2023-01-17
US10293002B2 (en) 2019-05-21
LT2880167T (lt) 2018-10-25
ES2679394T3 (es) 2018-08-27
WO2014022455A1 (en) 2014-02-06
US20170312318A1 (en) 2017-11-02
DK2880167T3 (en) 2018-07-30
PT2880167T (pt) 2018-07-23
HUE039520T2 (hu) 2019-01-28
HRP20181124T1 (hr) 2018-11-02
CY1120800T1 (el) 2019-12-11
US9649344B2 (en) 2017-05-16
CA2880691C (en) 2018-09-04
EP2880167A1 (en) 2015-06-10
JP6666961B2 (ja) 2020-03-18
EP2880167A4 (en) 2016-03-30
KR102100093B1 (ko) 2020-05-15
KR20150038531A (ko) 2015-04-08
US20190307809A1 (en) 2019-10-10
JP2015526432A (ja) 2015-09-10
CN104736711B (zh) 2017-09-08
CN104736711A (zh) 2015-06-24
PL2880167T3 (pl) 2018-12-31

Similar Documents

Publication Publication Date Title
BR112015002295A2 (pt) métodos e composições para indução in vivo de formação de célula beta pancreática
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
CL2015000901A1 (es) Modulación de la expresión de receptores androgénicos
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
UY35472A (es) Compuestos y sus usos en la modulacion de la hemoglobina
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
EA201001456A1 (ru) Новые гетероциклические соединения и их применение
UY35013A (es) Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
EA201100978A1 (ru) Схема приема агониста рецептора s1p
IN2012DN02710A (pt)
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
BR112013003160A2 (pt) tratamento de diabetes com células precursoras endócrinas pancráticas
GB0920703D0 (en) Compositions containing satiogens and methods of use
BR112013031307A2 (pt) métodos para tratamento de material lignocelulósico
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ECSP14013302A (es) Composiciones de yodo-povidona estable
UY33766A (es) COMPUESTOS CON ESTRUCTURA DE PIRIMIDINONA PARA USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR Lp-PLA2
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112013004616A2 (pt) diferenciação das células tronco embrionárias humanas
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2015012176A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
TR201911039T4 (tr) Ptp1b ile ilişkili bir hastalığın tedavisine yönelik aminosteroidler.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/07/2013, OBSERVADAS AS CONDICOES LEGAIS.